Latest News

States are rationing HIV medications through prior auth and formulary cuts to solve ADAP budget crises — a strategy that costs more, drives resistance, and concentrates harm on the most vulnerable.

Q2 2024 Watch: Prior authorization rollbacks in Medicaid HCV programs; ADAP and assistance program coverage.

Q1 2024 Watch: Pandemic Medicaid protections ended; millions lost coverage; ADAP and veterans updates.

HIV self-tests increase diagnosis but lack linkage to care; community support systems needed.

Payer denial of PrEP disproportionately fails Black women and marginalized communities.

Q4 2023 Watch: Bipartisan PEPFAR reauthorization push; ADAP coverage and Medicaid updates tracked.

Payers face regulatory scrutiny for systematic coverage denials and prior authorization abuse.

Q3 2023 Watch: HIV disparities coverage; debt ceiling crisis impacts; Medicaid disenrollment trends tracked.

Q2 2023 Watch: Braidwood decision impacts PrEP coverage; ADAP coverage analysis and Medicaid program updates.

Q1 2023 Watch: Tennessee rejecting federal HIV funding; updates on ADAPs, Medicaid, veterans care, and harm reduction.

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.

Monitoring report documents HCV treatment access challenges across ADAP, Medicaid, and VA systems.

Innovative HIV medications available but inaccessible: payer barriers block Cabenuva and Apretude access.

Community-based low-barrier HCV treatment for PWID significantly improves liver health outcomes.

West Virginia's fragmented HIV services across four entities creates barriers; centralization needed.

AMA survey: 93% of providers say prior authorizations delay care with 91% reporting negative clinical impact.

Medication abandonment disproportionately affects Black patients; PrEP users 41% more likely to abandon.

FDA extends Cabenuva to 2-month injections but insurance barriers continue to restrict patient access.

Payers restrict HCV treatment through utilization management; patient assistance programs fill the critical gap.

Stagnant CMS reimbursement rates since 2016 threaten addiction treatment provider closures and service access.